**Background of PCBD1 Antibody**
PCBD1 (Pterin-4-Alpha-Carbinolamine Dehydratase 1), also known as DCoH, is a bifunctional protein involved in tetrahydrobiopterin (BH4) regeneration and transcriptional coactivation. It serves as a cofactor for phenylalanine hydroxylase (PAH) by facilitating BH4 recycling, a critical process in neurotransmitter synthesis and phenylalanine metabolism. Additionally, PCBD1 interacts with hepatocyte nuclear factor 1α (HNF1α), modulating gene expression in glucose homeostasis and liver function.
PCBD1 antibodies are essential tools for studying its dual roles in metabolic regulation and disease. Mutations in PCBD1 are linked to hyperphenylalaninemia, a condition characterized by elevated phenylalanine levels, and may contribute to maturity-onset diabetes of the young (MODY) due to disrupted HNF1α signaling. Researchers use PCBD1 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions in tissues or cell lines.
These antibodies are also valuable in exploring PCBD1’s involvement in cancer, neurodegeneration, and metabolic disorders, given its impact on nitric oxide synthase activity and cellular redox balance. Commercial PCBD1 antibodies are typically raised in rabbits or mice, targeting specific epitopes to ensure specificity. Validations include knockout controls and functional assays to confirm their utility in both basic research and clinical diagnostics, aiding in understanding PCBD1’s pathophysiology and therapeutic potential.